JP2016523830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523830A5 JP2016523830A5 JP2016513039A JP2016513039A JP2016523830A5 JP 2016523830 A5 JP2016523830 A5 JP 2016523830A5 JP 2016513039 A JP2016513039 A JP 2016513039A JP 2016513039 A JP2016513039 A JP 2016513039A JP 2016523830 A5 JP2016523830 A5 JP 2016523830A5
- Authority
- JP
- Japan
- Prior art keywords
- alkynyl
- alkyl
- substituted
- absent
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 17
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 230000005865 ionizing radiation Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000002015 acyclic group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- -1 heterocyclic amine Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820447P | 2013-05-07 | 2013-05-07 | |
| US61/820,447 | 2013-05-07 | ||
| PCT/US2014/037110 WO2014182789A2 (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523830A JP2016523830A (ja) | 2016-08-12 |
| JP2016523830A5 true JP2016523830A5 (enExample) | 2017-06-15 |
Family
ID=51867859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513039A Pending JP2016523830A (ja) | 2013-05-07 | 2014-05-07 | 放射線緩和薬学的配合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9783515B2 (enExample) |
| EP (1) | EP2994457B1 (enExample) |
| JP (1) | JP2016523830A (enExample) |
| KR (1) | KR20160005356A (enExample) |
| CN (1) | CN105579439B (enExample) |
| AU (1) | AU2014262764B2 (enExample) |
| CA (1) | CA2911902A1 (enExample) |
| ES (1) | ES2860949T3 (enExample) |
| IL (1) | IL242493B (enExample) |
| SG (1) | SG11201509194SA (enExample) |
| WO (1) | WO2014182789A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| KR20160005356A (ko) * | 2013-05-07 | 2016-01-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 방사선완화 약제학적 제형 |
| WO2017156222A1 (en) * | 2016-03-09 | 2017-09-14 | The Regents Of The University Of California | Radiomitigating compounds, compositions and methods related thereto |
| EP3525787B1 (en) * | 2016-10-16 | 2026-02-18 | BCN Biosciences L.L.C. | Methods of treatment and pharmaceutical compositions using bcn057 or bcn512 |
| WO2019032739A1 (en) * | 2017-08-08 | 2019-02-14 | BCN Biosciences L.L.C. | METHODS OF TREATING RADIATION-INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND ASSOCIATED PATHOLOGICAL CONDITIONS USING COMPOUND 512 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| PL342447A1 (en) | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| US6407120B1 (en) | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| IT1313594B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Bisplatino complessi attivi per via orale. |
| EP1389204A4 (en) | 2001-04-26 | 2005-03-23 | Kolon Inc | NEW SULPHONAMIDE DERIVATIVES, THEIR INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS |
| JP5196787B2 (ja) * | 2003-11-14 | 2013-05-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα，β−不飽和スルホキシド |
| JP2005232101A (ja) * | 2004-02-20 | 2005-09-02 | Rikogaku Shinkokai | セレコキシブアミノアルキル誘導体 |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| MY140912A (en) | 2004-07-26 | 2010-01-29 | Du Pont | Mixtures of anthranilamide invertebrate pest control agents |
| US7615570B2 (en) | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2007029078A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| AU2007256597A1 (en) | 2006-06-09 | 2007-12-13 | Icos Corporation | Substituted phenyl acetic acids as DP-2 antagonists |
| CA2664365A1 (en) | 2006-09-28 | 2008-04-03 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| WO2010111713A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
| US8546397B2 (en) * | 2010-12-20 | 2013-10-01 | The Ohio State University Research Foundation | DNA methylation inhibitors |
| US9217000B2 (en) | 2011-02-18 | 2015-12-22 | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education | Targeted nitroxide agents |
| KR20160005356A (ko) * | 2013-05-07 | 2016-01-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 방사선완화 약제학적 제형 |
-
2014
- 2014-05-07 KR KR1020157034769A patent/KR20160005356A/ko not_active Ceased
- 2014-05-07 CA CA2911902A patent/CA2911902A1/en not_active Abandoned
- 2014-05-07 JP JP2016513039A patent/JP2016523830A/ja active Pending
- 2014-05-07 SG SG11201509194SA patent/SG11201509194SA/en unknown
- 2014-05-07 US US14/889,719 patent/US9783515B2/en active Active
- 2014-05-07 WO PCT/US2014/037110 patent/WO2014182789A2/en not_active Ceased
- 2014-05-07 ES ES14794084T patent/ES2860949T3/es active Active
- 2014-05-07 CN CN201480038705.0A patent/CN105579439B/zh active Active
- 2014-05-07 AU AU2014262764A patent/AU2014262764B2/en active Active
- 2014-05-07 EP EP14794084.5A patent/EP2994457B1/en active Active
-
2015
- 2015-11-08 IL IL242493A patent/IL242493B/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,192 patent/US9840483B2/en active Active
-
2017
- 2017-11-14 US US15/812,321 patent/US20180162827A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523830A5 (enExample) | ||
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| JP2016509047A5 (enExample) | ||
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| RU2012120760A (ru) | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления | |
| JP2019524883A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| JP2016534063A5 (enExample) | ||
| MX2010005342A (es) | Compuestos indola y metodos para tratar el dolor visceral. | |
| RU2013155586A (ru) | [1,3]оксазины | |
| RU2014138827A (ru) | Антагонисты рецептора андрогена и их применение | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| JP2015532295A5 (enExample) | ||
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| JP2013010792A5 (enExample) | ||
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| RU2624446C2 (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| JP2012513416A5 (enExample) | ||
| IN2014DN05869A (enExample) | ||
| RU2013152626A (ru) | ХИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДУЕМЫХ Ape1 |